← Back to Search

18F-NOS PET/CT Scan for Parkinson's Disease

Q: Will this research include geriatric patients?

<p>In order to participate in this clinical trial, applicants must fall between 18-75 years old. Comparatively, there are 81 clinical trials for patients who are under 18 and 889 for those over the age of 65.</p>

Q: Are there any restrictions on who can participate in this clinical trial?

<p>This study is looking for 30 people with <a href="https://www.withpower.com/clinical-trials/parkinson&#x27;s-disease">Parkinson's disease</a> to participate. Applicants must be between 18 and 75 years old. Other important criteria are as follows: participants must be willing to provide written informed consent, be willing to participate in the study in accordance with institutional and federal guidelines, have the capacity to give their own informed consent, and have a history of diagnosis of probable idiopathic PD.</p>

Phase < 1

Recruiting

Led By Jacob Dubroff, MD

Research Sponsored by University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosed with Parkinson's Disease at least 3 year prior to enrollment.

Participants will be 18-75 years of age.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 years

Awards & highlights

Study Summary

This trial is testing whether a PET scan can help diagnose or monitor Parkinson's disease by measuring inflammation in the brain.

Who is the study for?

This trial is for people aged 18-75 with Parkinson's disease or healthy individuals interested in brain inflammation research. Participants must understand the study and agree to its procedures. Those with neuropsychiatric disorders can join if it doesn't risk their safety or participation, as judged by an investigator.Check my eligibility

What is being tested?

The study tests a PET/CT scan using a tracer called 18F-NOS to detect brain inflammation, which could help diagnose or monitor Parkinson's disease treatment effectiveness.See study design

What are the potential side effects?

While not explicitly listed, potential side effects may include discomfort from the injection of the tracer, allergic reactions to the imaging drug, and exposure to radiation from the PET/CT scan.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I was diagnosed with Parkinson's Disease over 3 years ago.

Select...

I am between 18 and 75 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Characterize the uptake of [18F]NOS

Secondary outcome measures

Compare patterns of uptake

Compare peripheral blood inflammatory biomarkers

Trial Design

2Treatment groups

Experimental Treatment

Group I: Patient with Parkinson DiseaseExperimental Treatment1 Intervention

Subject should have a history of diagnosis of probable idiopathic PD derived from UK Brain Bank Diagnostic criteria per neurologist review. Subject must have been diagnosed with Parkinson's Disease at least 3 year prior to enrollment.

Group II: Healthy ControlExperimental Treatment1 Intervention

Subject must be a Healthy.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor

2,000 Previous Clinical Trials

42,880,058 Total Patients Enrolled

Jacob Dubroff, MDPrincipal InvestigatorUniversity of Pennsylvania

Media Library

[18F]NOS Clinical Trial Eligibility Overview. Trial Name: NCT04062526 — Phase < 1

Parkinson's Disease Research Study Groups: Patient with Parkinson Disease, Healthy Control

Parkinson's Disease Clinical Trial 2023: [18F]NOS Highlights & Side Effects. Trial Name: NCT04062526 — Phase < 1

[18F]NOS 2023 Treatment Timeline for Medical Study. Trial Name: NCT04062526 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Will this research include geriatric patients?

"In order to participate in this clinical trial, applicants must fall between 18-75 years old. Comparatively, there are 81 clinical trials for patients who are under 18 and 889 for those over the age of 65."

Answered by AI

Are there any restrictions on who can participate in this clinical trial?

"This study is looking for 30 people with Parkinson's disease to participate. Applicants must be between 18 and 75 years old. Other important criteria are as follows: participants must be willing to provide written informed consent, be willing to participate in the study in accordance with institutional and federal guidelines, have the capacity to give their own informed consent, and have a history of diagnosis of probable idiopathic PD."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT

2019. "Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04062526.

All > Parkinsons Disease > Parkinson